138 related articles for article (PubMed ID: 38178080)
21. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
[TBL] [Abstract][Full Text] [Related]
22. Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon Cancer.
Jiang W; Wang H; Dong X; Yu X; Zhao Y; Chen D; Yan B; Cheng J; Zhuo S; Wang H; Yan J
JAMA Surg; 2024 May; 159(5):519-528. PubMed ID: 38416471
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
[TBL] [Abstract][Full Text] [Related]
24. Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer.
Khalil L; Gao X; Switchenko JM; Alese OB; Akce M; Wu C; Diab M; El-Rayes BF; Shaib WL
Oncologist; 2022 Sep; 27(9):740-750. PubMed ID: 35648074
[TBL] [Abstract][Full Text] [Related]
25. Lymph node yield in the pathological staging of resected nonmetastatic colon cancer: The more the better?
Simões P; Fernandes G; Costeira B; Machete M; Baptista C; N Silva D; Leal-Costa L; Prazeres G; Correia J; Albuquerque J; Padrão T; Gomes C; Godinho J; Faria A; Casa-Nova M; Lopes F; Teixeira JA; F Pulido C; Oliveira H; Mascarenhas-Lemos L; Albergaria D; Maio R; Passos-Coelho JL
Surg Oncol; 2022 Aug; 43():101806. PubMed ID: 35841744
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.
André T; Vernerey D; Im SA; Bodoky G; Buzzoni R; Reingold S; Rivera F; McKendrick J; Scheithauer W; Ravit G; Fountzilas G; Yong WP; Isaacs R; Österlund P; Liang JT; Creemers GJ; Rakez M; Van Cutsem E; Cunningham D; Tabernero J; de Gramont A
Ann Oncol; 2020 Feb; 31(2):246-256. PubMed ID: 31959341
[TBL] [Abstract][Full Text] [Related]
27. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
André T; Boni C; Navarro M; Tabernero J; Hickish T; Topham C; Bonetti A; Clingan P; Bridgewater J; Rivera F; de Gramont A
J Clin Oncol; 2009 Jul; 27(19):3109-16. PubMed ID: 19451431
[TBL] [Abstract][Full Text] [Related]
28. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
31. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
Basile D; Broudin C; Emile JF; Falcoz A; Pagès F; Mineur L; Bennouna J; Louvet C; Artru P; Fratte S; Ghiringhelli F; André T; Derangère V; Vernerey D; Taieb J; Svrcek M;
Ann Oncol; 2022 Jun; 33(6):628-637. PubMed ID: 35306156
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Wilkinson NW; Yothers G; Lopa S; Costantino JP; Petrelli NJ; Wolmark N
Ann Surg Oncol; 2010 Apr; 17(4):959-66. PubMed ID: 20082144
[TBL] [Abstract][Full Text] [Related]
33. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
[TBL] [Abstract][Full Text] [Related]
34. DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer.
Li Y; Liao L; Kong L; Jiang W; Tang J; Han K; Hou Z; Zhang C; Zhou C; Zhang L; Sui Q; Xiao B; Mei W; Xu Y; Yu J; Hong Z; Pan Z; Ding P
Clin Transl Oncol; 2023 Jan; 25(1):218-225. PubMed ID: 36076121
[TBL] [Abstract][Full Text] [Related]
35. The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients.
Zhou C; Lu L; Huang Q; Tang Z; Tang R; Xiao Z; Xiao S
BMC Gastroenterol; 2023 Apr; 23(1):110. PubMed ID: 37020295
[TBL] [Abstract][Full Text] [Related]
36. Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)
Cohen R; Shi Q; Meyers J; Jin Z; Svrcek M; Fuchs C; Couture F; Kuebler P; Ciombor KK; Bendell J; De Jesus-Acosta A; Kumar P; Lewis D; Tan B; Bertagnolli MM; Philip P; Blanke C; O'Reilly EM; Shields A; Meyerhardt JA
Ann Oncol; 2021 Oct; 32(10):1267-1275. PubMed ID: 34293461
[TBL] [Abstract][Full Text] [Related]
37. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
[No Abstract] [Full Text] [Related]
39. Impact of tumor deposits on the prognosis and chemotherapy efficacy in stage III colorectal cancer patients with different lymph node status: A retrospective cohort study in China.
Li X; An B; Zhao Q; Qi J; Wang W; Zhang D; Li Z; Qin C
Int J Surg; 2018 Aug; 56():188-194. PubMed ID: 29936197
[TBL] [Abstract][Full Text] [Related]
40. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
